All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-05-30T07:14:37.000Z

The EMA grants GMI-1271 Orphan Drug Designation for AML

May 30, 2017
Share:

Bookmark this article

On 25th May 2017, the European Medicines Agency’s  (EMAs) Committee for Orphan Medicinal Products (COMP) granted Orphan Drug Designation for GMI-1271, a novel E-selectin (E-sel) antagonist , for the treatment of patients with Acute Myeloid Leukemia (AML).1  This comes after GMI-1271 was granted an orphan drug designation for the treatment of Relapsed or Refractory (R/R) AML by the U.S. Food and Drug Administration (FDA) earlier this month.

GMI-1271 is a novel antagonist of E-sel, (a cell adhesion molecule that contributes to leukemic cell survival pathways) and acts by disrupting leukemia cell survival pathways thus enhancing chemotherapy response.2,3

GMI-1271 is currently being investigated in the phase 2 portion of the phase 1/2 study (NCT02306291), which is aiming to assess the safety, efficacy and pharmacokinetics of this agent in combination with standard chemotherapy in patients with R/R AML and also in AML patients 60 years of age and older with newly diagnosed disease. Results from this study will be presented during this year’s American Society of Clinical Oncology Annual Meeting, taking place in Chicago between 2nd–6th June and also at the European Hematology Association (EHA) congress taking place in Madrid between 22nd–26th June.

  1. GlycoMimetics: GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia 2017 May 17. http://www.businesswire.com/news/home/20170525005579/en/GlycoMimetics%E2%80%99-GMI-1271-Receives-EU-Orphan-Drug-Designation [Accessed 2017 May 30].
  2. National Cancer Institute: E-selectin antagonist GMI-1271. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=767121. [Accessed 2017 May 18].
  3. DeAngelo D. J. et al. A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. 2016 Dec 5. Abstract 2029. 58th Annual Meeting of the American Society of Hematology, San Diego, Ca.
More about...

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 5 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox